

**LABORATORY REPORT**

NAME :	██████████	REFERRED BY :	██████████	VISIT NO :	██████████
AGE :	██████████	██████████	██████████	COLLECTED ON :	██████████
GENDER :	██	LAB MR# :	██████████	RECEIVED ON :	██████████
OP / IP / DG # :				APPROVED ON :	██████████
				REPORT STATUS :	Partial Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

Amfit Senior Citizen- Male

**HAEMATOLOGY**

**Complete Blood Counts** (Whole Blood - EDTA)

**(Automated Hematology Analyzer & Microscopy)**

Hemoglobin	15.4	13.0 - 17.0	g/dL
RBC Count	4.8	4.5 - 5.5	10 <sup>6</sup> /μL
Hematocrit	47.4	40 - 50	%
MCV(Mean Corpuscular Volume)	99.4	83 - 101	fL
MCH(Mean Corpuscular Hemoglobin)	<b>32.3 H</b>	27 - 32	pg
MCHC(Mean Corpuscular Hemoglobin Concentration)	32.5	31.5 - 34.5	g/dL
RDW	13.5	11.6 - 14	%
Total Leukocyte Count	<b>11.5 H</b>	4.0 - 11.0	10 <sup>3</sup> /μl

*Electrical impedance/Cell counter*

**Differential count % (VCSn Technology & light microscopy)**

Neutrophils	<b>85.0 H</b>	40-80%	%
Lymphocytes	<b>12.0 L</b>	20-40%	%
Monocytes	2.0	2-10%	%
Eosinophils	1.0	1-6%	%
Basophils	0.0	0-1%	%

**Differential Counts, Absolute(calculated)**

Absolute Neutrophil Count	<b>9.78 H</b>	2.0-7.0	10 <sup>3</sup> /μl
Absolute Lymphocyte Count	1.38	1.0-3.0	10 <sup>3</sup> /μl
Absolute Monocyte Count	0.23	0.2 - 1.0	10 <sup>3</sup> /μl
Absolute Eosinophil Count (AEC)	0.12	0.02-0.5	10 <sup>3</sup> /μl
Absolute Basophil Count	0.00	0.02 - 0.1	10 <sup>3</sup> /μl
Platelet Count	189	150 - 410	10 <sup>3</sup> /μl

*Electrical impedance/Cell counter or Manual*

MPV	----	7.5 - 11.5	fL
-----	------	------------	----



**LABORATORY REPORT**

<b>NAME</b> : [REDACTED]	<b>REFERRED BY</b> : [REDACTED]	<b>VISIT NO</b> :	[REDACTED]
<b>AGE</b> :	[REDACTED]	<b>COLLECTED ON</b> :	[REDACTED]
<b>GENDER</b> :	[REDACTED]	<b>RECEIVED ON</b> :	[REDACTED]
<b>OP / IP / DG #</b> :	<b>LAB MR#</b> :	<b>APPROVED ON</b> :	[REDACTED]
		<b>REPORT STATUS</b> :	Partial Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**Amfit Senior Citizen- Male**

**BIOCHEMISTRY**

**Lipid profile (Serum)**

Cholesterol Total - Serum <i>Enzymatic colorimetric</i>	158.0	<200 Desirable 200-239 Boderline >240 High	mg/dL
Triglycerides <i>Enzymatic colorimetric</i>	85.0	Normal: <150 Borderline-: 150-199 High risk 200-499 Very high risk >500	mg/dL
Cholesterol - HDL (Direct) <i>Enzymatic colorimetry</i>	44.0	High Risk :<40 Low Risk :>60	mg/dL
LDL Chol, Calculated	97.00		
VLDL (Very Low Density Lipoprotein) <i>Calculation</i>	17.0	<30	mg/dL
Cho/HDL Ratio	3.59	Normal : <4.0 Low risk : 4.0-6.0 High risk : >6.0	
LDL/HDL Ratio	2.20	Desirable/Low Risk: 0.5 - 3.0 Borderline/Moderate: 3.1 - 6.0 High Risk: >6.0	

**LFT(Bilirubin Total, Bilirubin Conjugated, (Serum)**

Bilirubin Total <i>Diazo method</i>	<b>1.50 H</b>	<1.1	mg/dL
Bilirubin Conjugated <i>Diazo method</i>	<b>0.90 H</b>	<=0.2	mg/dL
Bilirubin Unconjugated, Indirect <i>Calculation</i>	0.60	<1.0	mg/dL
Aspartate Aminotransferase (AST/SGOT) <i>Kinetic IFCC</i>	<b>111 H</b>	8 - 38	U/L
Alanine aminotransferase - (ALT / SGPT) <i>Kinetic IFCC</i>	<b>227 H</b>	4 - 44	U/L
Alkaline Phosphatase - ALP <i>Kinetic IFCC</i>	97.0	32 - 111	U/L

**Interpretation:**

1. In an asymptomatic patient, Non alcoholic fatty liver disease (NAFLD) is the most common cause of increased AST, ALT levels. NAFLD is considered as hepatic manifestation of metabolic syndrome.
2. In most type of liver disease, ALT activity is higher than that of AST; exception may be seen in Alcoholic Hepatitis, Hepatic Cirrhosis, and Liver neoplasia. In a patient with Chronic liver disease, AST:ALT ratio>1 is highly suggestive of

This is an electronically authenticated laboratory report.

Page 2 of 8



**LABORATORY REPORT**

<b>NAME</b> :	██████████	<b>REFERRED BY</b> :	██████████	<b>VISIT NO</b> :	██████████
<b>AGE</b> :	██████████		██████████	<b>COLLECTED ON</b>	██████████
<b>GENDER</b>	██████	<b>LAB MR#</b> :	██████████	<b>RECEIVED ON</b>	██████████
<b>OP / IP / DG #</b> :				<b>APPROVED ON</b>	██████████
				<b>REPORT STATUS</b>	: Partial Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**Amfit Senior Citizen- Male**

advanced liver fibrosis.

3. In known cases of Chronic Liver disease due to Viral Hepatitis B & C, Alcoholic liver disease or NAFLD, Enhanced liver fibrosis (ELF) test may be used to evaluate liver fibrosis.

4. In a patient with Chronic Liver disease, AFP and Des-gamma carboxyprothrombin (DCP)/PIVKA II can be used to assess risk for development of Hepatocellular Carcinoma.

**Blood Urea Nitrogen, BUN - Serum (Serum)**

Blood Urea Nitrogen (BUN) <i>spectrophotometry</i>	13.74	8.0 - 23.0	mg/dL
-------------------------------------------------------	-------	------------	-------

**Creatinine (Serum)**

Creatinine <i>Modified Jaffe Kinetic</i>	0.70	0.6 - 1.1	mg/dL
---------------------------------------------	------	-----------	-------

**Urea (Serum)**

Urea <i>Kinetic, Urease</i>	29.4	15 - 49	mg/dL
--------------------------------	------	---------	-------

**Uric acid (Serum)**

Uric acid <i>Uricase</i>	5.6	4.0 - 7.0	mg/dL
-----------------------------	-----	-----------	-------

**Calcium - Serum (Serum)**

Calcium - Serum <i>spectrophotometry</i>	8.40	8.4 - 10.2	mg/dL
---------------------------------------------	------	------------	-------

**Vitamin B12 (Serum)**

Vitamin B12 <i>CLIA</i>	301.0	211 - 911	pg/ml
----------------------------	-------	-----------	-------

**Interpretation:**

Vitamin B12 also referred to as cobalamin is a water soluble vitamin. The uptake in the gastro intestinal track depends on intrinsic factor, which is synthesised by gastric parietal cells

**Deficiency state:**

- Lack of intrinsic factor due to autoimmune atrophic gastritis
- Mal-absorption due to gastrectomy
- Inflammatory bowel disease
- Dietary deficiency (strict vegans)
- Vit B12 deficiency results in megaloblastic anaemia, peripheral neuropathy, dementia and depression

**Increased levels:**

- VIT B12 supplement intake
- Polycythaemia Vera.

This is an electronically authenticated laboratory report.

Page 3 of 8



**LABORATORY REPORT**

<b>NAME</b>	██████████	<b>REFERRED BY</b>	██████████	<b>VISIT NO</b>	: ██████████
<b>AGE</b>	██████████		██████████	<b>COLLECTED ON</b>	: ██████████
<b>GENDER</b>	: ██████	<b>LAB MR#</b>	: ██████████	<b>RECEIVED ON</b>	: ██████████
<b>OP / IP / DG #</b>	:			<b>APPROVED ON</b>	: ██████████
				<b>REPORT STATUS</b>	: Partial Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**Amfit Senior Citizen- Male**

**Vitamin D, 25-Hydroxy (Serum)**

Vitamin D, 25-Hydroxy CLIA	<b>20.1 L</b>	Deficiency<20 Insufficiency 20-30 Sufficiency 30- 100	ng/mL
-------------------------------	---------------	-------------------------------------------------------------	-------

**Interpretation:**

Severe vitamin D deficiency causes rickets in children and Osteomalacia in adults. Vitamin D assay is used for monitoring vitamin D replacement therapy.

**HbA1c - Glycated Hemoglobin (Whole Blood - EDTA)**

Glycated Hemoglobin, HbA1c FIA	<b>5.70 H</b>	Non-diabetic range: 4.8-5.6% Prediabetic range: 5.7-6.4% Diabetes range: >=6.5%	%
Estimated Average Glucose	116.9		mg/dL

**Interpretation:**

Note: HbA1c results may vary in situations of abnormal red cell turnover, such as pregnancy, recent blood loss or transfusion, or some anemias. In such cases only blood glucose criteria should be used to diagnose diabetes (ADA, 2014). Please correlate clinically.

**Glucose - Fasting (Fluoride Plasma - F)**

Glucose - Fasting Oxidase & Peroxidase	<b>229.0 H</b>	Normal:74-100 Pre-diabetic:100-125 Diabetic: >=126	mg/dL
-------------------------------------------	----------------	----------------------------------------------------------	-------

**T3 - Total (Tri Iodothyronine) (Serum)**

T3 - Total (Tri Iodothyronine) CLIA	1.1	0.60-1.81	ng/ml
----------------------------------------	-----	-----------	-------

**T4 - Total (Thyroxine - Total) (Serum)**

T4 - Total (Thyroxine - Total) CLIA	6.10	3.2-12.6	µg/dL
----------------------------------------	------	----------	-------

**Interpretation:**

**Note :**

1. Total T3 & T4 levels measure the hormone which is in the bound form and is not available to most tissues.
2. Severe systemic illness affects the thyroid binding proteins and can falsely alter Total T 4 levels in the absence of a primary thyroid disease. Hence Free T3 & T4 levels are recommended for accurate assessment of thyroid dysfunction.

**TSH, Thyroid Stimulating Hormone (Serum)**

TSH, Thyroid Stimulating Hormone ██████████	<b>5.809 H</b>	0.55 -4.78	µIU/mL
------------------------------------------------	----------------	------------	--------

This is an electronically authenticated laboratory report.



**LABORATORY REPORT**

NAME :	██████████	REFERRED BY :	██████████	VISIT NO :	██████████
AGE :	██████████		██████████	COLLECTED ON :	██████████
GENDER :	████	LAB MR# :	██████████	RECEIVED ON :	██████████
OP / IP / DG # :				APPROVED ON :	██████████
				REPORT STATUS :	Partial Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**Amfit Senior Citizen- Male**

CLIA

**Interpretation:**

TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m and at a minimum between 6-10 pm. The variation is of the order of 50%. Hence time of the day has influence on the measured serum TSH concentrations.

Alteration in concentration of Thyroid hormone binding protein can profoundly affect Total T3 and/or Total T4 levels especially in pregnancy and in patients on steroid therapy.

Unbound fraction ( Free,T4 /Free,T3) of thyroid hormone is biologically active form and correlate more closely with clinical status of the patient than total T4/T3 concentration. Values <0.03 uIU/mL need to be clinically correlated due to presence of a rare TSH variant in some individuals.

**Trimester specific guidelines recommended by American Thyroid Association(ATA) is as follow.**

Pregnant women	µIU/mL
1st trimester	0.10-2.5
2nd trimester	0.20-3.0
3rd trimester	0.30-3.0

**Iron Binding Capacity - Total (TIBC) (Serum)**

Iron <i>Spectrophotometry</i>	<b>33.0 L</b>	65-175	µg/dL
Unsaturated Iron Binding Capacity (UIBC) <i>Direct determination with FerroZine</i>	216.0	125 - 345	µg/dL
Iron Binding Capacity - Total (TIBC) <i>Spectrophotometry</i>	<b>249.0 L</b>	250-450	µg/dL
Transferrin Saturation Index (TSI) <i>FerroZine Colorimetric &amp; Calculation</i>	<b>13.2 L</b>	16-45	

This is an electronically authenticated laboratory report.

Page 5 of 8



**LABORATORY REPORT**

NAME :	██████████	REFERRED BY :	██████████	VISIT NO :	██████████
AGE :	██████████	LAB MR# :	██████████	COLLECTED ON :	██████████
GENDER :	████			RECEIVED ON :	██████████
OP / IP / DG # :				APPROVED ON :	██████████
				REPORT STATUS :	Partial Report



Test Name	Result	Biological Ref. Interval	Unit
<b>Amfit Senior Citizen- Male</b>			

**SEROLOGY AND IMMUNOLOGY**

**Hepatitis B Surface antigen (HBsAg) - Spot Test (Serum)**

Hepatitis B Surface antigen (HBsAg) - Spot Test    Non-reactive    Negative  
*Immunochromatography*

**Interpretation:**

**Test Observations:**

HBsAg is the first marker to appear after Hepatitis B infection and may be observed 2 or 3 weeks before the clinical and biological symptoms of the disease appear. Its period of presence may be very short (a few days) or very long (several years). HBs Ag persisting beyond 6 months in the serum denotes "chronic hepatitis". Because of the existence of numerous asymptomatic chronic carriers, hepatitis B represents an important transfusion hazard and the prevention of the transmission is based upon the detection of the HBs Ag at the time of each blood donation. This is a screening test and all positive samples must be confirmed by confirmatory tests like Neutralization assay or PCR. False positive results can be obtained due to the presence of other antigens or elevated levels of Rheumatoid factor (RF), although this is seen in less than 1% of the samples tested.

This is an electronically authenticated laboratory report.

Page 6 of 8



**LABORATORY REPORT**

NAME	██████████	REFERRED BY	: ██████████	VISIT NO	: ██████████
AGE	: ██████████		██████████	COLLECTED ON	: ██████████
GENDER	: ██████	LAB MR#	: ██████████	RECEIVED ON	: ██████████
OP / IP / DG #	:			APPROVED ON	: ██████████
				REPORT STATUS	: Partial Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**Amfit Senior Citizen- Male**

**BIOCHEMISTRY**

**Ferritin (Serum)**

Ferritin CLIA	<b>1,074.10 H</b>	22 - 322	ng/ml
------------------	-------------------	----------	-------

Kindly Correlate Clinically

**Interpretation:**

Ferritin is iron storage protein. Determination of ferritin is necessary in iron deficiency anemia , monitoring iron therapy and in differential diagnosis of anemia.

**Increased levels seen in**

- Hemochromatosis
- Porphyria
- Rheumatoid arthrosis
- Leukaemia
- Hodgkin's lymphoma
- Liver disease
- Multiple blood transfusion
- Acute phase reactant
- Increased in all inflammatory condition

**Decreased level**

Iron deficiency anemia.

**PSA Total (Prostatic Specific Antigen, Total) (Serum)**

PSA Total CLIA	0.25	0.0-3.50	ng/mL
-------------------	------	----------	-------

**Interpretation:**

This assay is used for monitoring patients with a history of prostate cancer and as an early indicator of recurrence and response to treatment. The test is commonly used for prostate cancer screening.

Result/s to Follow : URINE EXAMINATION - ROUTINE & MICROSCOPY (CUE)

██████████  
 ██████████/03807  
 MBBS, MD(BIOCHEMISTRY)  
 Consultant Biochemist

██████████  
 ██████████  
 Consultant Pathologist



**LABORATORY REPORT**

<b>NAME</b> :	██████████	<b>REFERRED BY</b> :	██████████	<b>VISIT NO</b> :	██████████
<b>AGE</b> :	██████████	<b>LAB MR#</b> :	██████████	<b>COLLECTED ON</b> :	██████████
<b>GENDER</b> :	██████████			<b>RECEIVED ON</b> :	██████████
<b>OP / IP / DG #</b> :				<b>APPROVED ON</b> :	██████████
				<b>REPORT STATUS</b> :	Partial Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**Amfit Senior Citizen- Male**

Disclaimer:

- All results released pertain to the specimen as received by the lab for testing and under the assumption that the patient indicated or identified on the bill/test requisition form is the owner of the specimen.
- Clinical details and consent forms, especially in Genetic testing, histopathology, as well as wherever applicable, are mandatory to be accompanied with the test requisition form. The non-availability of such information may lead to delay in reporting as well as misinterpretation of test results. The lab will not be responsible for any such delays or misinterpretations thereof.
- Test results are dependent on the quality of the sample received by the lab. In case the samples are preprocessed elsewhere (e.g., paraffin blocks), results may be compromised.
- Tests are performed as per the schedule given in the test listing and in any unforeseen circumstances, report delivery may be affected.
- Test results may show inter-laboratory as well as intra-laboratory variations as per the acceptable norms.
- Genetic reports as well as reports of other tests should be correlated with clinical details and other available test reports by a qualified medical practitioner. Genetic counselling is advised in genetic test reports by a qualified genetic counsellor, medical practitioner or both.
- Samples will be discarded post processing after a specified period as per the laboratory's retention policy. Kindly get in touch with the lab for more information.
- If accidental damage, loss, or destruction of the specimen is not attributable to any direct or negligent act or omission on the part of Ampath Labs or its employees, Ampath shall in no event be liable. Ampath lab's liability for a lack of services, or other mistakes and omissions, shall be restricted to the amount of the patient's payment for the pertinent laboratory services.

This is an electronically authenticated laboratory report.

Page 8 of 8

